Tuesday, December 21, 2010

Hepatitis C: Coffee and More Coffee

Also See;
Coffee Is A Good Thing Folks
In August of 2010 data from a case-control study showed that: moderate coffee consumption significantly reduced the risk of HCC by almost half in chronic HBV.
In November of this year at the AASLD meeting in Boston a presentation evaluated the relationship between drinking coffee and the response to HCV anti-viral treatment .
The Conclusion: Pre-treatment coffee intake was independently associated with improved virologic response during peginterferon alfa-2a and ribavirin in the HALT-C trial.
"daily coffee consumption of 3 or more cups was associated with 25.8% SVR vs 20.7% for 1- less then 3 cups and 12.7% for less then 1 cup and these are all statistically significant. Coffee increased EVR & week20 responses too"
A study from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), published in the January 2010 issue of Hepatology; has shown that in people with chronic hepatitis C virus who drink about two and a quarter cups of coffee (with caffeine) daily had milder liver fibrosis. However, researchers found that other beverages containing caffeine did not have the same effects.
The Dec 8th 2010 Abstract below suggests greater than three cups of coffee is associated with reduced histological activity .
Drink Up !
, Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.
J Hepatol. 210 Dec 8.Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A, Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, 94000 France.

AbstractRational The severity of chronic hepatitis C (CHC) is modulated by host and environmental factors. Several reports suggest that caffeine intake exerts hepatoprotective effects in patients with chronic liver disease.
The aim of this study was to evaluate the impact of caffeine consumption on activity grade and fibrosis stage in patients with CHC.
Methods 238 treatment-naı¨ve patients with histologically-proven CHC were included. Demographic, epidemiological, environmental, virological and metabolic features were collected, including daily consumptions of alcohol, cannabis, tobacco and caffeine during the six month preceding liver biopsy.
Daily caffeine consumption was estimated as the sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.
Histological activity grade and fibrosis stage were scored according to Metavir. Patients (154 men, 84 women, mean age: 45±11 years) were categorized according to caffeine consumption quartiles: group 1 (less then 225 n="59)," n="57)," n="62)" more then 678 mg/day, n=60).
There was a significant inverse relationship between activity grade and daily caffeine consumption: Activity grade more then A2 was present in 78%, 61%, 52% and 48% of patients in group 1, 2, 3 and 4, respectively (p less then 0.001). more then A2 (OR=0.32 (0.12-0.85)).
Caffeine intake showed no relation with the fibrosis stage.
Caffeine consumption greater than 408 mg/day (3 cups or more) is associated with reduced histological activity in patients with CHC. These findings support potential hepatoprotective properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.
PMID: 21145804
[PubMed - as supplied by publisher]

No comments:

Post a Comment